Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BRIP1 S624* |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BRIP1 S624* | soft tissue sarcoma | predicted - sensitive | Olaparib | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with Lynparza (olaparib) resulted in a clinical benefit rate of 62.5% (5/8) in advanced solid tumor patients harboring BRIP1 mutations, including a complete response in a patient with soft tissue sarcoma harboring BRIP1 S624* (reported as c.1871C>A) (PMID: 42105598). | 42105598 |